Coagulability in obstructive sleep apnea

Canadian Respiratory Journal

Volumn 18, Issue 6, 2011, Pages 338-348

  Liak, Christina ^a   Fitzpatrick, Michael ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Coagulation; Hemostasis; Hypercoagulable; Obstructive sleep apnea

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CATECHOLAMINE; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP APNEA SYNDROME; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84860471057     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/924629     Document Type: Review

References (86)

1. Young T, Peppard PE, Gottlieb DJ, . Epidemiology of obstructive sleep apnea: A population health perspective. Am J Respir Crit Care Med 2002;165:1217-39. (Pubitemid 34461732)
2. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: Eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008;31:1071-8.
3. Wolk R, Kara T, Somers VK. Sleep-disordered breathing and cardiovascular disease. Circulation 2003;108:9-12. (Pubitemid 36859012)
4. Minoguchi K, Yokoe T, Tazaki T, et al. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med 2007;175:612-7. (Pubitemid 46438946)
5. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006;173:910-6.
6. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 2005;365:1046-53. (Pubitemid 40386782)
7. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Cross-sectional results of the sleep heart health study. Am J Respir Crit Care Med 2001;163:19-25. (Pubitemid 32095247)
8. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034.
9. Dziewas R, Humpert M, Hopmann B, et al. Increased prevalence of sleep apnea in patients with recurring ischemic stroke compared with first stroke victims. J Neurol 2005;252:1394-8. (Pubitemid 41699032)
10. Schulz R. The vascular micromilieu in obstructive sleep apnoea. Eur Respir J 2005;25:780-2. (Pubitemid 40667673)
11. Ryan S, Taylor CT, McNicholas WT, Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112:2660-7. (Pubitemid 41532603)
12. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6. (Pubitemid 27200394)
13. Zubieta-Calleja GR, Paulev PE, Zubieta-Calleja L, Zubieta-Castillo G. Altitude adaptation through hematocrit changes. J Physiol Pharmacol 2007;58(Suppl 5):811-8. (Pubitemid 351346730)
14. Choi JB, Loredo JS, Norman D, et al. Does obstructive sleep apnea increase hematocrit? Sleep Breath 2006;10:155-60. (Pubitemid 44322497)
15. Hoffstein V, Herridge M, Mateika S, Redline S, Strohl KP. Hematocrit levels in sleep apnea. Chest 1994;106:787-91. (Pubitemid 24278885)
16. Krieger J, Sforza E, Barthelmebs M, Imbs JL, Kurtz D. Overnight decrease in hematocrit after nasal CPAP treatment in patients with OSA. Chest 1990;97:729-30. (Pubitemid 20095599)
17. Krieger J, Sforza E, Delanoe C, Petiau C. Decrease in haematocrit with continuous positive airway pressure treatment in obstructive sleep apnoea patients. Eur Respir J 1992;5:228-33.
18. Chin K, Ohi M, Kita H, et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;153:1972-6. (Pubitemid 26187928)
19. Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000;22:21.
20. Reinhart WH, Oswald J, Walter R, Kuhn M. Blood viscosity and platelet function in patients with obstructive sleep apnea syndrome treated with nasal continuous positive airway pressure. Clin Hemorheol Microcirc 2002;27:201-7. (Pubitemid 36160263)
21. Saarelainen S, Hasan J, Siitonen S, Seppala E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res 1996;5:181-5. (Pubitemid 26380247)
22. Zhang XL, Yin KS, Wang H, Su M, Yang Y. Effect of continuous positive airway pressure treatment on elderly Chinese patients with obstructive sleep apnea in the prethrombotic state. Chin Med J (Engl) 2003;116:1426-8. (Pubitemid 37184856)
23. Tazbirek M, Slowinska L, Skoczynski S, Pierzchala W. Short-term continuous positive airway pressure therapy reverses the pathological influence of obstructive sleep apnea on blood rheology parameters. Clin Hemorheol Microcirc 2009;41:241-9.
24. Dikmenoglu N, Ciftci B, Ileri E, et al. Erythrocyte deformability, plasma viscosity and oxidative status in patients with severe obstructive sleep apnea syndrome. Sleep Med 2006;7:255-61.
25. Steiner S, Jax T, Evers S, Hennersdorf M, Schwalen A, Strauer BE. Altered blood rheology in obstructive sleep apnea as a mediator of cardiovascular risk. Cardiology 2005;104:92-6. (Pubitemid 41197018)
26. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
27. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials. Thorax 2004;59:777-82. (Pubitemid 39215375)
28. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992;23:194-8.
29. von Kanel R, Loredo JS, Powell FL, Adler KA, Dimsdale JE. Short-term isocapnic hypoxia and coagulation activation in patients with sleep apnea. Clin Hemorheol Microcirc 2005;33:369-77. (Pubitemid 41750562)
30. Chin K, Kita H, Noguchi T, et al. Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome. QJM 1998;91:627-33. (Pubitemid 28438236)
31. von Kanel R, Le DT, Nelesen RA, Mills PJ, Ancoli-Israel S, Dimsdale JE. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 2001;19:1445-51. (Pubitemid 32730462)
32. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997;17:1539-44. (Pubitemid 27387775)
33. Heidi G, Dennis Winston TN, Ãỹvind H, Edward V, Hans Eirik F. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004;147:260-6.
34. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
35. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis 1993;100:1-12. (Pubitemid 23166003)
36. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005;294:1799-809.
37. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188-94.
38. Wessendorf TE, Thilmann AF, Wang Y, Schreiber A, Konietzko N, Teschler H. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000;162:2039.
39. Shitrit D, Peled N, Shitrit ABG, et al. An association between oxygen desaturation and D-dimer in patients with obstructive sleep apnea syndrome. Thromb Haemost 2005;94:544-7. (Pubitemid 41300850)
40. Saletu M, Nosiska D, Kapfhammer G, et al. Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA): Association of mild OSA with early atherosclerosis. J Neurol 2006;253:746-52. (Pubitemid 43980146)
41. von Kanel R, Natarajan L, Ancoli-Israel S, Mills PJ, Loredo JS, Dimsdale JE. Day/night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 2010;33:371-7.
42. Comondore VR, Cheema R, Fox J, et al. The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: A pilot feasibility randomized crossover trial. Lung 2009;187:17-22.
43. von Kanel RDJE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003;124:1956-67.
44. Saigo M, Hsue PY, Waters DD. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 2004;46:524-38. (Pubitemid 38781093)
45. Zamarron C, Ricoy J, Riveiro A, Gude F. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-6.
46. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002;106:491-6. (Pubitemid 34803696)
47. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801. (Pubitemid 30390240)
48. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9. (Pubitemid 23338739)
49. Thogersen AM, Jansson J-H, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7. (Pubitemid 28533841)
50. von Kanel R, Loredo JS, Ancoli-Israel S, et al. Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: An investigation in 2 different study samples. Metabolism 2007;56:969-76. (Pubitemid 46900834)
51. von Kanel R, Loredo JS, Ancoli-Israel S, Mills PJ, Natarajan L, Dimsdale JE. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 2007;131:733-9. (Pubitemid 46446864)
52. von Kanel R, Loredo JS, Ancoli-Israel S, Dimsdale JE. Association between sleep apnea severity and blood coagulability: Treatment effects of nasal continuous positive airway pressure. Sleep Breath 2006;10:139-46. (Pubitemid 44322495)
53. Ishikawa J, Hoshide S, Eguchi K, et al. Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome. J Hypertens 2008;26:1181-7. (Pubitemid 351670510)
54. Chung S, Yoon IY, Shin YK, et al. Endothelial dysfunction and C-reactive protein in relation with the severity of obstructive sleep apnea syndrome. Sleep 2007;30:997-1001. (Pubitemid 47221900)
55. Kapsimalis F, Varouchakis G, Manousaki A, et al. Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung 2008;186:209-17.
56. Lui MM, Lam JC, Mak HK, et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009;135:950-6. (Erratum 2009;135:1406)
57. Bhushan B, Guleria R, Misra A, et al. Obstructive sleep apnoea correlates with C-reactive protein in obese Asian Indians. Nutr Metabol Cardiovasc Dis 2009;19:184-9.
58. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007;132:843-51.
59. Ishida K, Kato M, Kato Y, et al. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest 2009;136:125-9.
60. Devaraj S, Xu DY, Jialal I. C-Reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
61. Wang Y, Yang H, Dong M, Wang Y, Yang H, Dong M. [Study on the levels of C-reactive protein and fibrinolytic activity in patients with obstructive sleep apnea syndrome.] Lin Chuang Erh Pi Yen Hou Ko Tsa Chih. J Clin Otorhinolaryngol 2004;18:147-8.
62. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380:41-6. (Pubitemid 26076234)
63. El Solh A, Akinnusi M, Berim I, Peter A, Paasch L, Szarpa K. Hemostatic implications of endothelial cell apoptosis in obstructive sleep apnea. Sleep Breath 2008;12:331-7.
64. Hayashi M, Fujimoto K, Urushibata K, et al. Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome. Respirology 2006;11:24-31.
65. Yan S-F, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/hypoxemia- induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999;19:2029-35. (Pubitemid 29422232)
66. De Meyer SF, Deckmyn H, Vanhoorelbeke K, De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009;113:5049-57.
67. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94.
68. Akinnusi ME, Paasch LL, Szarpa KR, Wallace PK, El Solh AA. Impact of nasal continuous positive airway pressure therapy on markers of platelet activation in patients with obstructive sleep apnea. Respiration 2009;77:25-31.
69. Bokinsky G, Miller M, Ault K, Husband P, Mitchell J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 1995;108:625-30.
70. Hui DS, Ko FW, Fok JP, et al. The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 2004;125:1768-75. (Pubitemid 38648410)
71. Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:648-52.
72. Oga T, Chin K, Tabuchi A, et al. Effects of obstructive sleep apnea with intermittent hypoxia on platelet aggregability. J Atherosc Thromb 2009;16:862-9.
73. Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002;69:229-34. (Pubitemid 34827837)
74. Eisensehr I, Ehrenberg BL, Noachtar S, et al. Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology 1998;51:188-95. (Pubitemid 28345382)
75. Shimizu M, Kamio K, Haida M, et al. Platelet activation in patients with obstructive sleep apnea syndrome and effects of nasalcontinuous positive airway pressure. Tokai J Exp Clin Med 2002;27:107-12. (Pubitemid 36460572)
76. Larsson P, Wallen N, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994;89:1951-7. (Pubitemid 24142768)
77. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 2006;100:343-8. (Pubitemid 43671127)
78. Sukegawa M, Noda A, Sugiura T, et al. Assessment of continuous positive airway pressure treatment in obstructive sleep apnea syndrome using 24-hour urinary catecholamines. Clin Cardiol 2005;28:519-22. (Pubitemid 41608271)
79. Minemura H, Akashiba T, Yamamoto H, Akahoshi T, Kosaka N, Horie T. Acute effects of nasal continuous positive airway pressure on 24-hour blood pressure and catecholamines in patients with obstructive sleep apnea. Intern Med 1998;37:1009-13.
80. Ambrosetti M, Lucioni A, Ageno W, Conti S, Neri M. Is venous thromboembolism more frequent in patients with obstructive sleep apnea syndrome? J Thromb Haemost 2004;2:1858-60. (Pubitemid 40192731)
81. Arnulf I, Merino-Andreu M, Perrier A, et al. Obstructive sleep apnea and venous thromboembolism. JAMA 2002;287:2655-6. (Pubitemid 34533542)
82. Epstein MD, Segal LN, Ibrahim SM, et al. Snoring and the risk of obstructive sleep apnea in patients with pulmonary embolism. Sleep 2010;33:1069-74.
83. Bosanquet JP, Bade BC, Zia MF, et al. Patients with venous thromboembolism appear to have higher prevalence of obstructive sleep apnea than the general population. Clin Appl Thromb Hemost Dec 2010 (E-pub ahead of print).
84. Hasegawa R, Shiomi T, Sasanabe R, et al. Sleep apnea syndrome in patients with pulmonary thromboembolism. Psychiatry Clin Neurosci 2000;54:342-3. (Pubitemid 30431850)
85. Othman M, Gordon SP, Iscoe S. Repeated inspiratory occlusions in anesthetized rats acutely increase blood coagulability as assessed by thromboelastography. Respir Physiol Neurobiol 2010;171:61-6.
86. Guardiola JJ, Matheson PJ, Clavijo LC, Wilson MA, Fletcher EC. Hypercoagulability in patients with obstructive sleep apnea. Sleep Med 2001;2:517-23. (Pubitemid 34026951)